XBIO Konsensus Analis
Opini analis bullish dan bearish, target harga 12 bulan, potensi kenaikan
JUAL6 analis
Beli Kuat
00,0%
Beli
00,0%
Tahan
350,0%
Jual
116,7%
Jual Kuat
233,3%
Riwayat Pendapatan
EPS aktual vs perkiraan, kejutan %, tingkat keberhasilan, tanggal pendapatan berikutnya
Kejutan Rata-rata
-0.07%
Periode
EPS Aktual
EPS Estimasi
Kejutan
30 Juni 2025
$-0.45
$-0.65
0.20%
31 Maret 2025
$-0.59
$-0.73
0.14%
31 Des. 2024
$-0.68
$-0.20
-0.48%
30 Sep. 2024
$-0.28
$-0.14
-0.14%
Perbandingan rekan (sub-industri GICS)
Metrik utama vs rekan sektor
Ticker
Kapitalisasi Pasar
P/E
Pendapatan YoY
Margin Bersih
ROE
Margin Kotor
XBIO
—
-1.4
19.0%
—
—
—
BOLT
$11M
-0.3
0.07%
-433.7%
-102.2%
—
CDIO
—
—
—
—
—
—
ACXP
$6M
-0.5
—
—
-180.3%
—
PMCB
$8M
-0.3
—
—
-56.7%
—
BRTX
$10M
-0.7
-10.3%
-3959.4%
-547.6%
93.4%
DRMA
—
—
—
—
—
—
GOVX
$296.2K
—
-37.1%
-862.3%
-645.9%
—
LABT
—
—
—
—
—
—
BCAB
—
-0.6
—
—
—
—
Fundamental Lengkap
Semua metrik per tahun — laporan laba rugi, neraca, arus kas
Laporan Laba Rugi17
Data Laporan Laba Rugi Tahunan untuk XBIO
Metrik
Tren
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue
$3M
$3M
$3M
$2M
$1M
$436.9K
$17.1K
$0
$8M
$3M
$0
$0
Cost of Revenue
·
·
·
·
·
·
·
·
·
·
·
$0
Gross Profit
·
·
·
·
·
·
·
·
·
·
·
$0
R&D Expense
$3M
$3M
$3M
$5M
$3M
$2M
$5M
$3M
$4M
$44M
$3M
$6M
SG&A Expense
$3M
$3M
$4M
$4M
$4M
$3M
$5M
$4M
$7M
$7M
$6M
$7M
Operating Expenses
$6M
$7M
$7M
$8M
$7M
$14M
$13M
$7M
·
·
·
$13M
Operating Income
$-3M
$-4M
$-5M
$-7M
$-6M
$-14M
$-13M
$-7M
$-4M
$-47M
$-10M
$-13M
Interest Expense
·
·
·
·
·
·
·
·
$1.8K
$729.6K
$267.0K
$4.7K
Interest Income
·
·
·
·
·
·
·
·
·
·
·
$19.0K
Other Non-op
$5.7K
$-5.7K
$25.4K
$-1.6K
$1.1K
$-492
$3.3K
$-24.6K
$-24.6K
$-85.4K
$-235.4K
$-326.9K
Pretax Income
·
·
·
·
·
·
·
·
·
·
·
$-14M
Income Tax
$0
$0
$0
$0
$0
$-3M
$0
$0
$0
$0
$0
$0
Net Income
$-3M
$-4M
$-4M
$-7M
$-6M
$-11M
$-13M
$-7M
$-4M
$-54M
$-13M
$-14M
EPS (Basic)
$-1.58
$-2.57
$-2.71
$-4.61
$-0.55
·
·
·
·
·
·
·
EPS (Diluted)
$-1.58
$-2.57
$-2.71
$-4.61
$-0.55
·
·
·
·
·
·
·
Shares (Basic)
1,701,571
1,541,339
1,528,210
1,422,443
10,279,408
·
·
·
·
·
·
·
Shares (Diluted)
1,701,571
1,541,339
1,528,210
1,422,443
10,279,408
·
·
·
·
·
·
·
Neraca25
Data Neraca Tahunan untuk XBIO
Metrik
Tren
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Cash & Equivalents
$8M
$6M
$9M
$13M
$18M
$12M
$10M
$571.6K
$6M
$4M
$132.2K
$3M
Receivables
·
·
·
·
·
·
·
·
$0
$3M
$0
·
Prepaid Expense
$166.3K
$422.0K
$603.8K
$556.1K
$479.4K
$842.0K
$722.1K
$555.9K
$285.0K
$1M
$247.3K
$204.0K
Current Assets
$8M
$7M
$10M
$14M
$19M
$12M
$11M
$1M
$6M
$8M
$4M
$3M
PP&E (Net)
·
·
·
$0
$0
$0
$757
$5.0K
$27.8K
$42.4K
$62.0K
$119.4K
PP&E (Gross)
·
·
·
$0
$50.2K
$57.0K
$57.0K
$89.4K
$358.3K
$349.1K
$332.3K
$586.1K
Accum. Depreciation
·
·
·
$0
$50.2K
$57.0K
$56.3K
$84.4K
$330.5K
$306.7K
$270.2K
$466.7K
Goodwill
·
·
·
·
·
$0
$9M
$3M
$3M
$3M
$3M
$3M
Other Non-current Assets
$313.9K
$313.9K
$1M
$1M
$1M
$810.0K
$1M
$705.7K
$724.7K
$66.3K
$129.3K
$199.3K
Total Assets
$8M
$7M
$11M
$15M
$20M
$13M
$22M
$14M
$19M
$21M
$17M
$16M
Accounts Payable
$258.1K
$283.6K
$240.8K
$287.4K
$362.5K
$327.4K
$931.1K
$934.1K
$786.8K
$1M
$2M
$852.8K
Accrued Liabilities
$709.9K
$610.6K
$568.8K
$785.8K
$1M
$574.0K
$464.0K
$664.0K
$1M
$838.9K
$1M
$1M
Current Liabilities
$968.0K
$894.3K
$809.6K
$1M
$1M
$936.9K
$1M
$2M
$2M
$2M
$7M
$3M
Capital Leases
·
·
·
·
·
$27.0K
$0
·
·
·
·
·
Deferred Tax
·
·
·
·
·
$27.0K
$3M
$3M
$3M
$3M
$3M
$3M
Other Non-current Liabilities
·
·
·
·
·
·
·
$0
$0
$19.9K
$38.8K
$56.4K
Total Liabilities
$968.0K
$894.3K
$809.6K
$1M
$1M
$964.0K
$4M
$5M
$5M
$5M
$10M
$6M
Common Stock
$2.3K
$1.5K
$1.5K
$1.5K
$13.5K
$8.8K
$6.1K
$811
$9.0K
$8.7K
$4.9K
$150.0K
Paid-in Capital
$212M
$208M
$208M
$208M
$206M
$194M
$188M
$168M
$165M
$164M
$100M
$91M
Retained Earnings
$-200M
$-197M
$-193M
$-189M
$-183M
$-177M
$-166M
$-153M
$-146M
$-142M
$-88M
$-76M
Treasury Stock
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
AOCI
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$575.7K
Stockholders' Equity
$7M
$6M
$10M
$14M
$18M
$12M
$17M
$10M
$14M
$16M
$7M
$10M
Liabilities + Equity
$8M
$7M
$11M
$15M
$20M
$13M
$22M
$14M
$19M
$21M
$17M
$16M
Shares Outstanding
2,291,056
1,542,139
1,540,684
1,516,659
13,439,612
8,745,207
6,065,441
783,865
8,717,541
4,585,800
4,585,800
139,297,282
Arus Kas8
Data Arus Kas Tahunan untuk XBIO
Metrik
Tren
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
D&A
·
·
·
$0
$0
$1.0K
·
·
·
·
$56.1K
$88.7K
Stock-based Comp
$64.8K
$171.8K
$283.1K
$511.5K
$410.4K
$468.9K
$806.1K
$1M
$2M
$2M
$2M
$2M
Operating Cash Flow
$-2M
$-3M
$-4M
$-5M
$-5M
$-4M
$-6M
$-6M
$1M
$-9M
$-5M
$-13M
CapEx
·
·
·
·
·
·
·
$0
$9.3K
$16.8K
$1.7K
$57.7K
Investing Cash Flow
·
·
$0
$-500.0K
$0
$0
$2.0K
$22.5K
$-9.3K
$-16.8K
·
·
Stock Issued
$4M
$0
·
$0
$11M
$5M
$0
·
·
·
$0
$10M
Financing Cash Flow
$4M
$0
·
$0
$11M
$5M
$16M
$1M
$0
$13M
·
·
Taxes Paid
·
·
·
·
·
·
·
·
·
·
·
$0
Per Saham1
Data Per Saham Tahunan untuk XBIO
Metrik
Tren
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
EPS (TTM)
$-1.58
$-2.57
$-2.71
$-4.61
$-0.55
·
·
·
·
·
·
·
Tingkat Pertumbuhan3
Data Tingkat Pertumbuhan Tahunan untuk XBIO
Metrik
Tren
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue YoY
19.0%
-1.6%
48.8%
47.1%
165.6%
·
·
·
·
·
·
·
Revenue CAGR 3Y
20.4%
29.1%
79.8%
·
·
·
·
·
·
·
·
·
Revenue CAGR 5Y
46.8%
·
·
·
·
·
·
·
·
·
·
·
Valuasi (TTM)5
Data Valuasi (TTM) Tahunan untuk XBIO
Metrik
Tren
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
Revenue TTM
$3M
$3M
$3M
$2M
$1M
$436.9K
$17.1K
$0
$8M
$3M
$0
$0
Net Income TTM
$-3M
$-4M
$-4M
$-7M
$-6M
$-11M
$-13M
$-7M
$-4M
$-54M
$-13M
$-14M
P/E
-1.4
-1.6
-1.3
-0.6
-23.5
·
·
·
·
·
·
·
P / Tangible Book
0.7
1.0
0.5
3.2
9.4
14.6
·
·
·
·
·
·
Earnings Yield
-72.8%
-64.4%
-78.5%
-161.8%
-4.3%
·
·
·
·
·
·
·
Laporan Laba Rugi14
Data Triwulanan Laporan Laba Rugi untuk XBIO
Metrik
Tren
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Revenue
$660.6K
$806.9K
$766.3K
$1M
$589.9K
$593.3K
$648.8K
$614.2K
$726.4K
$510.8K
$672.0K
$611.2K
$651.0K
$605.8K
$487.0K
$414.2K
R&D Expense
$552.0K
$661.4K
$773.4K
$756.5K
$656.6K
$879.0K
$1M
$368.0K
$933.8K
$944.3K
$975.6K
$1M
$903.2K
$595.3K
$1M
$398.8K
SG&A Expense
$1M
$647.6K
$615.9K
$815.2K
$657.8K
$656.6K
$705.7K
$745.7K
$1M
$834.9K
$952.0K
$737.2K
$946.0K
$925.7K
$857.2K
$863.2K
Operating Expenses
$2M
$1M
$1M
$2M
$1M
$2M
$2M
$1M
$2M
$2M
$2M
$2M
$2M
$2M
$2M
$1M
Operating Income
$-971.7K
$-502.1K
$-623.0K
$-544.7K
$-724.4K
$-942.4K
$-1M
$-499.5K
$-1M
$-1M
$-1M
$-1M
$-1M
$-915.2K
$-2M
$-847.8K
Interest Income
$42.1K
$45.8K
·
·
$34.2K
$39.2K
·
·
·
·
·
·
·
·
·
·
Other Non-op
$-72
$-21
$159
$4.0K
$1.5K
$78
$-7.2K
$1.5K
$-21
$52
$404
$-666
$21.1K
$4.5K
$986
$-1.7K
Income Tax
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
$0
Net Income
$-929.7K
$-456.4K
$-579.1K
$-509.9K
$-688.7K
$-903.1K
$-1M
$-436.7K
$-1M
$-1M
$-1M
$-1M
$-1M
$-856.6K
$-1M
$-804.0K
EPS (Basic)
$-0.41
$-0.20
$-0.21
$-0.33
$-0.45
$-0.59
$-0.68
$-0.28
$-0.83
$-0.78
$-0.77
$-0.69
$-0.69
$-0.56
$-2.03
$-0.56
EPS (Diluted)
$-0.41
$-0.20
$-0.21
$-0.33
$-0.45
$-0.59
$-0.68
$-0.28
$-0.83
$-0.78
$-0.77
$-0.69
$-0.69
$-0.56
$-2.03
$-0.56
Shares (Basic)
2,294,364
2,291,056
-2,924,846
1,542,139
1,542,139
1,542,139
-3,081,866
1,541,722
1,540,799
1,540,684
-3,045,766
1,532,600
1,524,717
1,516,659
-14,855,930
1,431,659
Shares (Diluted)
2,294,364
2,291,056
-2,924,846
1,542,139
1,542,139
1,542,139
-3,081,866
1,541,722
1,540,799
1,540,684
-3,045,766
1,532,600
1,524,717
1,516,659
-14,855,930
1,431,659
EBITDA
$-971.7K
$-502.1K
·
$-544.7K
$-724.4K
$-942.4K
·
$-499.5K
$-1M
$-1M
·
$-1M
$-1M
$-915.2K
·
$-847.8K
Neraca18
Data Triwulanan Neraca untuk XBIO
Metrik
Tren
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Cash & Equivalents
·
$7M
·
·
·
$5M
·
$7M
$7M
$8M
$9M
$10M
$11M
$12M
$13M
$14M
Prepaid Expense
$182.3K
$247.8K
$166.3K
$946.4K
$573.9K
$313.6K
$422.0K
$188.1K
$716.4K
$552.0K
$603.8K
$1M
$1M
$876.5K
$556.1K
$319.1K
Current Assets
$7M
$8M
$8M
$5M
$5M
$5M
$7M
$7M
$8M
$8M
$10M
$11M
$12M
$13M
$14M
$14M
Other Non-current Assets
$313.9K
$313.9K
$313.9K
$0
$0
$313.9K
$313.9K
$1M
$1M
$1M
$1M
$704.4K
$704.4K
$844.4K
$1M
$1M
Total Assets
$7M
$8M
$8M
$5M
$5M
$6M
$7M
$8M
$9M
$9M
$11M
$12M
$13M
$14M
$15M
$16M
Accounts Payable
$322.5K
$558.8K
$258.1K
$578.2K
$346.8K
$240.3K
$283.6K
$243.3K
$283.6K
$210.5K
$240.8K
$448.6K
$221.3K
$259.2K
$287.4K
$202.8K
Accrued Liabilities
·
·
$709.9K
·
·
·
$610.6K
·
·
·
$568.8K
·
·
·
$785.8K
·
Current Liabilities
$895.0K
$958.2K
$968.0K
$1M
$903.4K
$667.9K
$894.3K
$1M
$2M
$716.5K
$809.6K
$1M
$871.3K
$856.4K
$1M
$1M
Capital Leases
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
$0
Total Liabilities
$895.0K
$958.2K
$968.0K
$1M
$903.4K
$667.9K
$894.3K
$1M
$2M
$716.5K
$809.6K
$1M
$871.3K
$856.4K
$1M
$1M
Common Stock
$2.3K
$2.3K
$2.3K
$1.5K
$1.5K
$1.5K
$1.5K
$1.5K
$1.5K
$1.5K
$1.5K
$1.5K
$1.5K
$15.2K
$1.5K
$14.3K
Paid-in Capital
$212M
$212M
$212M
$208M
$208M
$208M
$208M
$208M
$208M
$208M
$208M
$208M
$208M
$208M
$208M
$207M
Retained Earnings
$-201M
$-200M
$-200M
$-199M
$-199M
$-198M
$-197M
$-196M
$-196M
$-194M
$-193M
$-192M
$-191M
$-190M
$-189M
$-188M
Treasury Stock
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
$5M
AOCI
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
$253.7K
Stockholders' Equity
$6M
$7M
$7M
$4M
$4M
$5M
$6M
$7M
$7M
$9M
$10M
$11M
$12M
$13M
$14M
$15M
Liabilities + Equity
$7M
$8M
$8M
$5M
$5M
$6M
$7M
$8M
$9M
$9M
$11M
$12M
$13M
$14M
$15M
$16M
Shares Outstanding
2,343,181
2,293,757
2,291,056
1,542,139
1,542,139
1,542,139
1,542,139
1,542,139
1,541,101
1,540,684
1,540,684
1,532,600
1,532,600
15,166,596
1,516,659
14,316,596
Arus Kas3
Data Triwulanan Arus Kas untuk XBIO
Metrik
Tren
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Stock-based Comp
$52.0K
$11.3K
$14.0K
$15.9K
$15.7K
$19.3K
$25.1K
$27.5K
$42.1K
$77.1K
$74.6K
$70.3K
$69.4K
$68.9K
$118.7K
$137.4K
Operating Cash Flow
$-875.5K
$-536.4K
$-242.7K
$-658.2K
$-383.8K
$-1M
$-674.0K
$-459.0K
$-525.1K
$-1M
$-793.0K
$-949.6K
$-1M
$-1M
$-750.9K
$-1M
Investing Cash Flow
·
·
·
·
·
·
·
·
·
·
·
$0
·
·
$0
$0
Profitabilitas5
Data Triwulanan Profitabilitas untuk XBIO
Metrik
Tren
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Operating Margin
-147.1%
-62.2%
·
-53.0%
-122.8%
-158.8%
·
-81.3%
-184.1%
-248.3%
·
-187.6%
-184.1%
-151.1%
·
-204.7%
Net Margin
-140.7%
-56.6%
·
-49.7%
-116.8%
-152.2%
·
-71.1%
-175.4%
-234.0%
·
-172.7%
-161.4%
-141.4%
·
-194.1%
EBITDA Margin
-147.1%
-62.2%
·
-53.0%
-122.8%
-158.8%
·
-81.3%
-184.1%
-248.3%
·
-187.6%
-184.1%
-151.1%
·
-204.7%
ROA
-15.1%
-6.7%
·
-7.8%
-9.6%
-11.9%
·
-4.4%
-11.7%
-10.3%
·
-7.7%
-7.2%
-5.4%
·
-4.4%
ROE
-17.7%
-7.6%
·
-9.3%
-11.6%
-13.1%
·
-4.9%
-13.2%
-11.1%
·
-8.3%
-7.8%
-5.8%
·
-4.6%
Likuiditas & Solvabilitas2
Data Triwulanan Likuiditas & Solvabilitas untuk XBIO
Metrik
Tren
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Current Ratio
7.4
7.9
·
4.6
5.9
8.2
·
7.0
5.0
11.7
·
10.5
13.8
15.0
·
13.5
Quick Ratio
·
7.7
·
·
·
7.7
·
6.8
4.6
10.9
·
9.1
12.3
14.0
·
13.2
Efisiensi1
Data Triwulanan Efisiensi untuk XBIO
Metrik
Tren
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Asset Turnover
0.1
0.1
·
0.2
0.1
0.1
·
0.1
0.1
0.0
·
0.0
0.0
0.0
·
0.0
Per Saham5
Data Triwulanan Per Saham untuk XBIO
Metrik
Tren
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Book Value / Share
$2.59
$3.03
·
$2.57
$2.89
$3.32
·
$4.56
$4.83
$5.63
·
$7.11
$7.75
$0.85
·
$1.01
Revenue / Share
$0.29
$0.35
·
$0.67
$0.38
$0.38
·
$0.40
$0.47
$0.33
·
$0.40
$0.43
$0.04
·
$0.03
Cash Flow / Share
·
$-0.23
·
·
·
$-0.65
·
·
·
$-0.75
·
·
·
$-0.07
·
·
Cash / Share
·
$3.20
·
·
·
$3.35
·
$4.44
$4.74
$5.08
·
$6.38
$7.00
$0.79
·
$0.97
EPS (TTM)
$-1.39
$-1.57
·
$-1.65
$-2.15
$-2.48
·
$-2.58
$-2.99
$-2.72
·
$-2.50
$-3.71
$-3.14
·
$-2.71
Valuasi (TTM)9
Data Triwulanan Valuasi (TTM) untuk XBIO
Metrik
Tren
Q2 2026
Q1 2026
Q4 2025
Q3 2025
Q2 2025
Q1 2025
Q4 2024
Q3 2024
Q2 2024
Q1 2024
Q4 2023
Q3 2023
Q2 2023
Q1 2023
Q4 2022
Q3 2022
Revenue TTM
$3M
$3M
·
$3M
$3M
$2M
·
$2M
$2M
$2M
·
$2M
$2M
$2M
·
$2M
Net Income TTM
$-3M
$-3M
·
$-3M
$-3M
$-4M
·
$-4M
$-5M
$-4M
·
$-4M
$-5M
$-6M
·
$-6M
Market Cap
$7M
$6M
·
$5M
$6M
$4M
·
$7M
$6M
$6M
·
$8M
$5M
$62M
·
$77M
P/E
-2.1
-1.7
·
-1.9
-1.8
-1.1
·
-1.7
-1.4
-1.4
·
-2.0
-0.9
-1.3
·
-2.0
P/S
2.2
2.0
·
1.7
2.4
1.6
·
2.7
2.5
2.4
·
3.3
2.4
33.7
·
49.0
P/B
1.1
0.9
·
1.2
1.4
0.8
·
0.9
0.8
0.7
·
0.7
0.4
4.8
·
5.3
P / Tangible Book
1.1
0.9
·
1.2
1.4
0.8
·
0.9
0.8
0.7
·
0.7
0.4
4.8
·
5.3
P / Cash Flow
·
-11.5
·
·
·
-4.0
·
·
·
-5.0
·
·
·
-55.9
·
·
Earnings Yield
-47.8%
-58.6%
·
-52.5%
-54.9%
-95.0%
·
-59.7%
-73.5%
-72.2%
·
-51.0%
-113.1%
-77.3%
·
-50.5%
Laporan Keuangan
Laporan laba rugi, neraca, arus kas — tahunan, 5 tahun terakhir
Laporan Laba Rugi
2025-12-31
2024-12-31
2023-12-31
2022-12-31
2021-12-31
Pendapatan
$3M
$3M
$3M
$2M
$1M
Laba Bersih
$-3M
$-4M
$-4M
$-7M
$-6M
EPS Dilusian
$-1.58
$-2.57
$-2.71
$-4.61
$-0.55
Metrik Saya
Daftar pantauan pribadi Anda — baris yang dipilih dari Fundamental Lengkap
📊
Pilih metrik yang penting bagi Anda — klik ➕ di sebelah baris mana pun di Fundamental Lengkap di atas.
Pilihan Anda disimpan dan mengikuti Anda di semua ticker.
Pemilik institusional (13F)
8 pengaju · $422K total · Per tanggal 30 Juni 2026
Institusi yang melaporkan kepemilikan saham ini dalam SEC Form 13F triwulanan mereka. Hanya posisi panjang; satu pengaju dapat muncul dua kali untuk leg opsi terpisah. Kaki put/call offset yang besar biasanya mencerminkan pembuatan pasar atau inventaris yang dilindungi, bukan keyakinan arah.
Aktivitas institusional — Q2 2026 vs kuartal sebelumnya
Posisi baru
Posisi yang keluar
Meningkat
Menurun
Perubahan bersih saham
3
(+3 vs Kuartal sebelumnya)
0
(-5 vs Kuartal sebelumnya)
0
(-1 vs Kuartal sebelumnya)
3
(+1 vs Kuartal sebelumnya)
-10K
Dibandingkan dengan Q1 2026. Pengajuan Formulir 13F SEC jatuh tempo dalam waktu 45 hari setelah akhir kuartal ditambah kelonggaran singkat untuk pengaju terlambat — kuartal yang masih dalam jangka waktu tersebut dilewati demi pasangan terakhir yang dilaporkan sepenuhnya.
Orang dalam dari pengajuan SEC Form 3/4/5; bersih = hanya P/S pasar terbuka
Aktivis & pemilik 5%+
3 saham
Investor yang mengajukan Jadwal 13D SEC — kepemilikan manfaat di atas 5% dengan niat untuk memengaruhi penerbit (kepemilikan aktivis, kampanye dewan, M&A). Setiap baris menunjukkan status terbaru yang diketahui dari posisi pengaju tersebut.
Pengaju
Diajukan
Kepemilikan
Status
Tujuan
Pengajuan
CLS Therapeutics, LLC, CLS Therapeutics Ltd., Dmitry Genkin, Victor Tets, Georgy Tets, M. Scott Maguire
×3 pengajuan
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Kepemilikan ETF
Dimiliki oleh 1 ETF
Bobot mencerminkan kepemilikan ekuitas langsung (N-PORT) saja; dana berbasis leverage atau derivatif mungkin memiliki eksposur swap tambahan yang tidak ditampilkan.